Market Report Source

Overview

Introduction

Cypress Bioscience is a biotechnology company specializing in products for the treatment of patients with Functional Somatic Syndromes, such as Fibromyalgia Syndrome (FMS) and other central nervous system (CNS) disorders. In December 2007, it along with its partner Forest Laboratories, submitted a New Drug Application (NDA) for its lead product candidate, milnacipran, for the treatment of FMS.

Scope

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies

Highlights

Cypress Bioscience has one lead product candidate, milnacipran, for the treatment of FMS which is currently awaiting approval from the FDA. Cypress Bioscience derives entire revenues from the collaboration agreement with Forest Laboratories for the development and marketing of milnacipran. During the period 2002-2006, the company’s total revenues decreased at a CAGR of 9%, from $6 million to $4 million. Cypress Bioscience’s collective contributor to sales growth out to 2010 will be royalties and collaboration revenues earned in connection with the development and commercialization of milnacipran in alliance with Forest Laboratories. Revenues from this stream are expected to contribute the entire absolute sales growth of +$98 million.

Reasons to Purchase

Access all the important information and analysis on the company in a single report Understand company’s strengths, weaknesses, opportunities and threats along with business strategy and value chain Gain access to company’s adjusted five year financial data along with key ratios and market capitalization.

Table of Contents

Overview
Catalyst
Summary
Company Structure
Company Overview and Key Facts
Business Description
History
Company Financials
Stock Market Performance
P&L
Balance Sheet
Cash Flow
Products & Services
Pipeline Products
AC Forecast Product Sales
Competitors and Strategic Business Relationships
Top Competitors
Key Suppliers
Key Clients
Shareholding Structure
Strategy
Company View
Corporate Strategy
SWOT Analysis
Overview
Strengths
Weaknesses
Opportunities
Threats
Value Chain Analysis
Overview
Product Development
Scorecard
Overview
Scorecard Analysis
Key Employees
List of Key Employees
Key Employee Biographies
Financial and Operational Overview
Financial and Operational Overview
Appendix
Ask the analyst
Datamonitor consulting
Disclaimer

FIGURES
Figure 1: Cypress Bioscience – Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)

TABLES
Table 1: Cypress Bioscience – Key Facts
Table 2: Cypress Bioscience – Year-End Share Price and Market Capitalization, 2002-2006 ($)
Table 3: Cypress Bioscience – Key Events Impacting Share Price Performance
Table 4: Cypress Bioscience – Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)
Table 5: Cypress Bioscience – Operating Cost Ratio Analysis, 2002-2006 (% of total revenues)
Table 6: Cypress Bioscience – Balance Sheet, 2002-2006 ($ Mn)
Table 7: Cypress Bioscience – Cash Flow, 2002-2006 ($ Mn)
Table 8: Cypress Bioscience – Collaboration Pipeline Products
Table 9: Cypress Bioscience – Forecast Sales, 2006-2010 ($ Mn)
Table 10: Cypress Bioscience – Top Competitors
Table 11: Cypress Bioscience – Key Suppliers
Table 12: Cypress Bioscience – Key Clients
Table 13: Cypress Bioscience – Key Shareholders
Table 14: Cypress Bioscience – SWOT Analysis Summary
Table 15: Cypress Bioscience – Value Chain Analysis
Table 16: Cypress Bioscience – Scorecard
Table 17: Cypress Bioscience – Key Employees
Table 18: Cypress Bioscience – Financial and Operational Overview